DualityBio appoints CMO ahead of key expansion phase

China-based biotech DualityBio has named Hua Mu as its global chief medical officer, as the company prepares to ramp up its international clinical development efforts and advance toward key capital market milestones.

Dr Mu, who trained as a physician in China and earned a doctorate at the University of California, Berkeley, brings decades of experience from roles in multinational pharmaceutical companies, biotech firms, and investment groups. He has overseen multiple drug programs from early-stage development through to commercialization.

His appointment signals a strategic push by DualityBio to expand its global footprint, particularly through international multicenter clinical trials. Founder and chief executive John Zhu said Dr Mu’s appointment comes “at a pivotal moment,” adding that his “full-cycle development experience in multinational pharma and hands-on expertise in the globalization of China’s innovative drugs” will support the company’s next phase of growth.